Ventria Bioscience acquires Meristem Therapeutics' recombinant lactoferrin IP
Ventria Bioscience is acquiring exclusive ownership rights to intellectual property relating to Meristem Therapeutics' recombinant human lactoferrin.
Ventria Bioscience is to acquire intellectual property relating to recombinant lactoferrin developed by French biotechnology company Meristem Therapeutics.
Under the terms of the agreement, Ventria Bioscience will obtain exclusive royalty-free ownership rights for specific patents in the US, France and Canada in exchange for a one-off payment.
The agreement includes patents relating to recombinant human lactoferrin, which is the active ingredient in Ventria Bioscience's lead drug candidate VEN100.
VEN100 is currently being developed as a preventive treatment for antibiotic-associated diarrhoea in high-risk adults.
Scott Deeter, president and chief executive officer of Ventria Bioscience, said: "The patents acquired today cover important components of our product pipeline.
"The decision to purchase this intellectual property is significant because it removes the encumbrance of ongoing royalty and milestone payments, thereby enhancing the future economics of our products that use recombinant human lactoferrin."
Ventria Bioscience has solved the problem of producing commercial-scale yields of recombinant human lactoferrin using its proprietary ExpressTec technology platform.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.